Le Lézard
Classified in: Science and technology
Subjects: PDT, TDS

Apposite Technologies Announces 10G4 High Density 10 Gbps Network Emulator for Datacenter Migration Projects


LOS ANGELES, Aug.16, 2017 /PRNewswire/ -- Apposite® Technologies, the industry leader in application performance testing over wide area networks (WAN), today announced the release of Netropy® 10G4, adding to Apposite's family of award-winning WAN emulators. The Netropy 10G4 offers eight 10 Gigabit Ethernet ports and can support wire rate traffic up to 80 Gbps in a single chassis.

Apposite Technologies. (PRNewsfoto/Apposite Technologies)

Datacenter architects are adding more and more 10 gigabit links between sites to ensure sufficient bandwidth to support storage networks and application servers. However, the distance between datacenter sites can have a huge impact on application throughput and responsiveness, due to latency and packet loss of the network.  

The Netropy 10G4 allows cloud application developers and datacenter architects to simulate multiple 10 Gigabit network links in their lab before going live. By emulating the real network conditions, they can experiment with traffic management policies and optimize application performance.

"Datacenters managers are constantly judging how much extra bandwidth they require to support new services or migration projects," said Neal Roche, CEO of Apposite Technologies. "We help them answer the question: how will legacy applications perform when migrated to a remote datacenter?"

The Netropy 10G4 is also ideal for multi-user testing. By taking advantage of Apposite's unique engine-locking capabilities, four separate users can each run their own, independent tests on a dedicated pair of 10 Gbps ports, providing a highly compact and cost-effective alternative to purchasing multiple emulators.

Apposite Technologies will be exhibiting at VM World in Las Vegas, August 27-30 at booth # 1813.

About Apposite Technologies
Apposite Technologies' award-winning WAN emulation products provide IT professionals with high precision tools for benchmarking the performance of applications across wide area networks. Distinguished by industry-best ease-of-use and unmatched value, Apposite's Linktropy and Netropy appliances inform critical decisions impacting bandwidth investment, application deployment, and end-user satisfaction. Apposite's network emulation products are used by leading enterprises, network application developers, government and military organizations, and telecoms carriers around the world.

 

SOURCE Apposite Technologies


These press releases may also interest you

at 01:15
The first-ever public auction of the epic satoshi held by CoinEx, the leading global cryptocurrency exchange, ended on April 25, 2024, at 16:00 (UTC). As the first example shown in history, the auction attracted global users for 35 bids, and the epic...

at 01:05
Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) and Peugeot Sport, the motorsports division of Stellantis, today announced their partnership to simulate and optimize the aerodynamics of the PEUGEOT 9X8 Hybrid Hypercar for the 2024 endurance...

at 00:39
World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly...

25 avr 2024
The Industrial Technology Research Institute (ITRI) convened the 2024 ITRI Net Zero Day in Taipei, accelerating industry's transition to net-zero emissions. The event highlighted key innovations and successful business cases, focusing on the...

25 avr 2024
The report titled "Identity Governance & Administration Market by Component (Services, Solution), Modules (Access Certification & Compliance Control, Access Management, Identity Lifecycle Management), Organization Size, Deployment, Vertical - Global...

25 avr 2024
The report titled "Contract Research Organization Services Market by Type (Clinical Research Services, Consulting Services, Data Management Services), Trial Phase (Phase I, Phase II, Phase III), Therapeutic Area, Molecule Type, End-User - Global...



News published on and distributed by: